GLP-1s, Peptides, and The Trillion-Dollar Health Revolution

Braidwell founder Alex Karnal argues oral GLP-1s just triggered a trillion-dollar shift from reactive to preventive medicine, with new scripts jumping 50% in months.

• Oral GLP-1 (Wegovy) launched at $150/month drove weekly new scripts from 200,000 to 300,000 in just a few months, a ~4x faster launch than injectable Zepbound.
• Eli Lilly data shows GLP-1s reduce progression from pre-diabetic to diabetic by 94%; Karnal calls GLP-1 the most important molecule across all five health axes.
• Middle-aged adults carry 30–50% lifetime probability of heart attack or stroke; available medicines (statins, PCSK9 inhibitors) could cut that risk below 10%.
• Compounded GLP-1s captured 15–20% of the addressable market at ~$200–250/month, proving massive price elasticity that branded players ignored.
• AI drug discovery companies can go from target to testable molecule in one month vs. years historically; Karnal names Laya Sciences and Anaba as examples already doing this.
• AI biotech moat will come from proprietary lab-generated science tokens, not public literature — which Karnal notes is often unreplicable and data-corrupt.
• Karnal expects full robotic automation of drug discovery labs within 5–10 years, with agentic systems running 24/7 experiments and scientists freed from bench work.
• FDA under Marty Makary is cutting redundant animal studies and using AI to process filings, signaling regulatory acceleration that aligns with the citizen pharmacology movement.

2026-04-21 · Watch on YouTube